CellRev’s proprietary enzyme technology improves scalability, consistency, and control in cell culture systems, enabling a faster, easier route to clinical trials and optimised manufacturing for production at scale.
Our enzymes cleave the cell-to-cell extracellular matrix components in a dose-controlled manner, without harming the cells, to improve culture homogeneity, boost cell viability, and increase process yield.
Our principal product, AggreGuard, has been developed to optimise microcarrier-based culture systems. We have products in development covering iPSC and HEK293 processing.
Company Details
- Employees
- 9
- Founded
- -
- Address
- The Biosphere, Newcastle,tyne And Wear Ne4,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cellularevolution.co.uk
- Keywords
- Bioprocessing, Adherent Cell Culture, Process Engineering, Cell Biology, Cell Growth, High-Density Processing.
- HQ
- Newcastle, Tyne and Wear
Cellrev Questions
Cellrev's website is cellularevolution.co.uk
Cellrev's LinkedIn profile is https://uk.linkedin.com/company/cellrev
Cellrev has
9 employees.
View email and phone details for 9
employees at Cellrev.
Cellrev's industry is
Biotechnology Research
Cellrev's top competitors are
Nunabio Limited,
Quantumdx,
Iksuda Therapeutics,
The Biosphere,
Marrabio,
Alcyomics,
Newcells Biotech Ltd,
Atelerix Ltd.,
Northgene™,
3d Bio-Tissues.
Cellrev's categories are Biotechnology Research
Cellrev's founding year is 2019
